MapLight Therapeutics is a biopharmaceutical company that focuses on brain disorders such as autism, Parkinson’s, and schizophrenia. MapLight is developing a discovery platform to uncover the individual circuits that misfire in brain disorders and aim to target those circuits with effective, safe therapeutics that improve patient lives.
The company’s novel approach combines proprietary, patented innovations such as optogenetics, STARmap, and transcriptomics. Using these strategies, MapLight has developed a strong pipeline of therapeutics of two lead compounds (under programmes ML-004 and ML-007C-MA) in clinical trials as of October 2023, demonstrating multiple indications and disorders, including social deficits related to autism and unwanted movements related to Parkinson’s disease. As of October 2023, the five of the remaining compounds under the pipeline were in preclinical, Phase I, and Phase II stages.
Funding and financials
In October 2023, MapLight Therapeutics raised USD 225 million in a Series C funding round led by Novo Holdings, with participation from new investors, including 5AM Ventures and Cowen Healthcare Investments. The funds were expected to be used for the development of ML-007C-MA, MapLight's novel therapeutic candidate, into Phase 2 trials for schizophrenia and Alzheimer's disease psychosis, set for 2024, and to bolster the company's other pipeline programs.
No investor data is available
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.